← Back to Search

Thrombolytic Agent

Exposed for Stroke (STROKE TeleQOL Trial)

N/A
Waitlist Available
Research Sponsored by Thomas Jefferson University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights

Summary

To study the effect of a telemedicine model of stroke care on patient-based outcomes.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
HRQoL
Secondary study objectives
mRS

Side effects data

From 2017 Phase 4 trial • 81 Patients • NCT02159521
10%
Deep vein thrombosis
8%
Nausea
6%
Procedural haemorrhage
4%
Pain in extremity
4%
Back pain
3%
Anxiety
3%
Haematoma
3%
Pruritus
3%
Asthma
3%
Anaemia
3%
Bradycardia
3%
Contusion
3%
Haematuria
1%
Joint effusion
1%
Sinusitis
1%
Hypertension
1%
Pneumonia aspiration
1%
Rash
1%
Abdominal pain
1%
Atrial fibrillation
1%
Injection site haemorrhage
1%
Groin pain
1%
Oedema
1%
Urinary tract infection
1%
Upper gastrointestinal haemorrhage
1%
Cardiac failure congestive
1%
Epistaxis
1%
Dizziness
1%
Drug hypersensitivity
1%
Pulmonary embolism
1%
Uterine haemorrhage
1%
Heparin-induced thrombocytopenia
1%
Venous occlusion
1%
Pelvic venous thrombosis
1%
Haemorrhage
1%
Constipation
1%
Post procedural haemorrhage
1%
Osteomyelitis
1%
Septic shock
1%
Oxygen saturation decreased
1%
Ecchymosis
1%
Hypoaesthesia
1%
Migraine
1%
Ventricular extrasystoles
1%
Blood fibrinogen decreased
1%
Lactic acidosis
1%
Haemoptysis
1%
Dyspnoea
1%
Insomnia
1%
Skin ulcer
1%
Dysuria
1%
Squamous cell carcinoma
100%
80%
60%
40%
20%
0%
Study treatment Arm
EkoSonic® Endovascular System

Trial Design

2Treatment groups
Experimental Treatment
Group I: Un-exposedExperimental Treatment0 Interventions
AIS patients evaluated through RTP and who do not receive i.v. tPA
Group II: ExposedExperimental Treatment1 Intervention
AIS patients evaluated through RTP and who receive i.v. tPA
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Alteplase
FDA approved

Find a Location

Who is running the clinical trial?

Thomas Jefferson UniversityLead Sponsor
456 Previous Clinical Trials
149,096 Total Patients Enrolled
4 Trials studying Stroke
2,101 Patients Enrolled for Stroke
Genentech, Inc.Industry Sponsor
1,550 Previous Clinical Trials
568,064 Total Patients Enrolled
11 Trials studying Stroke
16,766 Patients Enrolled for Stroke
~28 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top